Abstract Tuberculosis (TB) is a disease which kills two million people every year and infects over one-third of the world 0 s population. Eighteen new 8-substituted berberine derivatives were synthesized and evaluated for their anti-mycobacterial activities against Mycobacterium tuberculosis (M. tuberculosis) strain H 37 Rv. Among these compounds, compound 6i was the most effective antitubercular agent with an MIC of 1.0 mg/mL. Most importantly, compound 6i also exhibited a potent effect against clinically isolated rifampicin-and isoniazid-resistant M. tuberculosis strains, suggesting a different mode of action from the current drugs. Therefore, it shows potential for the development of new anti-TB agents.
Introduction
Tuberculosis (TB), emergence of multidrug-resistance TB (MDR-TB), and extensively drug-resistance TB (XDR-TB) are the major causes of death from infectious diseases worldwide. It is anticipated that there will be about 9.8 million new TB cases this year, more than in any other year in history 1, 2 . Five percent of all TB cases are now estimated to be MDR-TB, which is resistant to at least rifampin (RIF) and isoniazid (INH), the two most important first-line drugs used currently in clinic 3, 4 . The overall incidence of TB in HIV-positive patients is 50 times that of the rate for HIV-negative individuals [5] [6] [7] . The difficulty in managing TB is the prolonged treatment duration, the emergence of drug resistance and co-infection with HIV/AIDS. However, no new chemical scaffold for the treatment of this disease has been introduced in the past 40 years 8, 9 and there is an urgent need to discover new classes of molecules without crossresistance with current anti-mycobacterial drugs 9 . In the search for novel-scaffold of anti-mycobacterial agents, berberine (1) derivative libraries constructed in our laboratory were screened against drug-susceptible Mycobacterium tuberculosis (M. tuberculosis) strain H 37 Rv, with RIF and INH as positive drugs [10] [11] [12] . The primary structureactivity relationship (SAR) analysis indicated that the 8-substituted dihydropseudoberberine (2) and dihydropalmatine (3) derivatives showed moderate antibacterial activity against M. tuberculosis (Fig. 1) . Based on these preliminary results, a series of new 8-substituted 2 and 3 derivatives was designed, prepared, and evaluated for their anti-mycobacterial effect against the drug-susceptible H 37 R V and drug-resistance strains of M. tuberculosis.
Results and discussion

SAR analysis for anti-mycobacterial activity
Eighteen designed derivatives were first measured for their anti-tubercular activities against the multiplication of drug-susceptible M. tuberculosis strain H 37 Rv with the microplate alamar blue assay (MABA). RIF and INH were used as the reference drugs. The structures of the 18 analogs and their anti-mycobacterial activities are shown in Tables 1 and 2 .
The SAR study was mainly focused on the substituents at the 8-position of 2. Replacement of hydrogen at the 8-position (ÀR 1 ) with methyl, ethyl, n-propyl, i-propyl, nbutyl, n-pentyl, cyclopentyl, n-hexyl, or phenyl, respectively, generated nine new analogs (6a-i). These compounds showed moderate activity with MIC ranges between 1.0 and 32 mg/mL. Among these analogs, compounds 6f-h afforded ideal anti-tubercular activities at an MIC value of 2.0 mg/mL. Compound 6i, bearing phenyl on position 8, exhibited the best activity with an MIC value of 1.0 mg/mL. It indicated that introduction of a large substituent at the 8-position might be beneficial for anti-mycobacterial activity.
Next, SAR analysis was moved to the modifications at the 8-positions of 3. A methyl, ethyl, n-propyl, i-propyl, n-butyl, n-pentyl, cyclopentyl, n-hexyl, and n-octyl was attached at the 8-position of dihydropalmatine, generating nine new analogs (7a-i) which were prepared and tested. Compounds 7d, 7g and 7h showed moderate activity at an MIC of 4.0 mg/mL. Compound 7i bearing n-octyl at the 8-position exhibited ideal activity with an MIC value of 2.0 mg/mL.
Anti-resistant TB effect of the compound 6i
As compound 6i possessed excellent activity against drugsusceptible M. tuberculosis strain H 37 Rv with an MIC of 1.0 mg/mL, it was further examined for its effect on the MDR strains of M. tuberculosis. In this experiment, M. tuberculosis strains 44, 83 and 699 were used; these strains were isolated from patients with tuberculosis in China and were resistant to both RIF and INH. As described in Table 3 , RIF and INH showed decreased activity against these drug-resistant strains partially or completely with MIC ranging between 4 and 432 mg/mL. However, compound 6i afforded a reasonable Figure 1 Chemical structures of compounds 1, 2 and 3.
inhibition against MDR strains, with MIC ranges of 2.0-16 mg/mL. The results revealed that compound 6i was active for either drug-susceptible M. tuberculosis and those resistant to RIF and INH, suggesting a novel mechanism of action against TB.
Conclusions
In conclusion, 18 new derivatives of dihydropseudoberberine (2) and dihydropalmatine (3) with various substituents at position 8 were synthesized and evaluated for their antimycobacterial activities against M. tuberculosis H 37 Rv. SAR analysis revealed that a large group at the 8-position might be beneficial for the anti-mycobacterial activity. This might be an explanation as to why compounds 2 and 3 do not show significant activities against M. tuberculosis. Among the test compounds, compound 6i exhibited significant activity against both drug-susceptible and MDR strains of M. tuberculosis, suggesting a different mode of action against TB in comparison to current drugs. Thus, it has been selected as a lead compound for the development of anti-TB agents.
Experimental section
Chemistry
Melting point (mp) was obtained with CXM-300 melting point apparatus and uncorrected. The 1 H NMR spectra was performed on a Varian Inova 400 MHz spectrometer (Varian, San Francisco, CA) and 13 C NMR on a Bruker Avance III 400 spectrometer in DMSO-d 6 , with Me 4 Si as the internal standard. ESI high-resolution mass spectra (HRMS) were recorded on an Autospec UItima-TOF mass spectrometer (Micromass UK Ltd., Manchester, UK). Flash chromatography was performed on CombiflashRf 200 (Teledyne, Nebraska, USA), particle size 0.038 mm.
Eighteen new 8-substituted dihydroberberine derivatives were synthesized with 4 11, 12 (synthesized in our laboratory) or commercially available 5 as the starting materials, as described in Scheme 1.
Grignard reagents were prepared via Magnesium turnings (3.8 g) with the corresponding alkyl and phenyl iodides (0.13 mol) in absolute ether (100 mL) at 0 1C. The synthesized Grignard reagents were slowly added to the suspension of dry 4 or 5 (0.03 mol) in absolute ether (100 mL) under N 2 protection at 0 1C 13, 14 . After refluxing for 2 h, saturated NH 4 Cl solution (200 mL) was added to quench the reaction. The aqueous phase was extracted with ethyl acetate (3 Â 100 mL) and the combined organic layers were washed with saturated brines (100 mL) and dried (Na 2 SO 4 ). The mixture was concentrated in vacuo to give 2 or 3. The residue was acidified by 4 M HCl/EtOH (20 mL) at room temperature, and the solvent was removed by evaporation. The products in series 6 or 7 were purified via flash column chromatography using methanol/dichloromethane as the gradient eluent. 148.8, 148.1, 147.4, 135.7, 123.8, 119.7, 119.4, 110.4, 109.2,  108.8, 108.4, 103.1, 67.4, 55.8, 55.6, 50.1, 34.2, 31.9, 30.8 , 2H), 4.05 (s, 3H), 3.94 (s, 3H), 3.92 (s, 3H) 
